Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease

Naseri, Kaveh; Saadati, Saeede; Yari, Zahra; Askari, Behzad; Mafi, Davood; Hoseinian, Pooria; Asbaghi, Omid; Hekmatdoost, Azita; Courten, Barbora de

doi:10.3390/nu14153224

Cited by 11 publications

(9 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From now on, the clinical trials of curcumin are primary about cancer [ 214 ], AD [ 215 ], metabolic syndrome [ 216 ], polycystic ovarian syndrome [ 217 ] et al In addition, clinical trials of nanocurcumin [ 190 ] and its bioavailability research [ 218 ] were also reported. Many clinical trials have shown the role of curcumin in improving diseases, but small number of clinical trials also found that curcumin has no significant benefit to related diseases [ 219 ]. The related information about curcumin clinical trials was shown in Table 4 .…”

Section: Curcumin Clinical Application Statusmentioning

confidence: 99%

Pharmacological Mechanisms and Clinical Applications of Curcumin: Update

Hao¹,

Chu²,

Jing-xuan³

et al. 2023

Aging and disease

View full text Add to dashboard Cite

Curcumin, a well-known hydrophobic polyphenol extracted from the rhizomes of turmeric (Curcuma longa L.), has attracted great interest in the last ten years due to its multiple pharmacological activities. A growing body of evidence has manifested that curcumin has extensive pharmacological activities including anti-inflammatory, anti-oxygenation, lipid regulation, antiviral, and anticancer with hypotoxicity and minor adverse reactions. However, the disadvantages of low bioavailability, short half-life in plasma, low drug concentration in blood, and poor oral absorption severely limited the clinical application of curcumin. Pharmaceutical researchers have carried out plenty of dosage form transformations to improve the druggability of curcumin and have achieved remarkable results. Therefore, the objective of this review summarizes the pharmacological research progress, problems in clinical application and the improvement methods of curcumin’s druggability. By reviewing the latest research progress of curcumin, we believe that curcumin has a broad clinical application prospect for its wide range of pharmacological activities with few side effects. The deficiencies of lower bioavailability of curcumin could be improved by dosage form transformation. However, curcumin in the clinical application still requires further study regarding the underlying mechanism and clinical trial verification.

show abstract

Section: Curcumin Clinical Application Statusmentioning

confidence: 99%

Pharmacological Mechanisms and Clinical Applications of Curcumin: Update

Hao¹,

Chu²,

Jing-xuan³

et al. 2023

Aging and disease

View full text Add to dashboard Cite

show abstract

“…Subsequent findings from a randomized controlled trial involving 52 NAFLD patients corroborated these conclu- markers, were observed. Nonetheless, the likelihood of severe fatty liver and metabolic syndrome was reduced (Naseri et al, 2022).…”

Section: A Clinical Glimpse At Polyphenolic Compounds Protecting Agai...mentioning

confidence: 99%

“…However, no further effects of curcumin on cardiometabolism, including adipose tissue‐related indicators, atherogenic markers, and insulin resistance markers, were observed. Nonetheless, the likelihood of severe fatty liver and metabolic syndrome was reduced (Naseri et al, 2022).…”

Section: A Clinical Glimpse At Polyphenolic Compounds Protecting Agai...mentioning

confidence: 99%

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Hu,

Zhang,

Wei

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

This review focuses on the potential ameliorative effects of polyphenolic compounds derived from human diet on hepatic diseases. It discusses the molecular mechanisms and recent advancements in clinical applications. Edible polyphenols have been found to play a therapeutic role, particularly in liver injury, liver fibrosis, NAFLD/NASH, and HCC. In the regulation of liver injury, polyphenols exhibit anti‐inflammatory and antioxidant effects, primarily targeting the TGF‐β, NF‐κB/TLR4, PI3K/AKT, and Nrf2/HO‐1 signaling pathways. In the regulation of liver fibrosis, polyphenolic compounds effectively reverse the fibrotic process by inhibiting the activation of hepatic stellate cells (HSC). Furthermore, polyphenolic compounds show efficacy against NAFLD/NASH by inhibiting lipid oxidation and accumulation, mediated through the AMPK, SIRT, and PPARγ pathways. Moreover, several polyphenolic compounds exhibit anti‐HCC activity by suppressing tumor cell proliferation and metastasis. This inhibition primarily involves blocking Akt and Wnt signaling, as well as inhibiting the epithelial‐mesenchymal transition (EMT). Additionally, clinical trials and nutritional evidence support the notion that certain polyphenols can improve liver disease and associated metabolic disorders. However, further fundamental research and clinical trials are warranted to validate the efficacy of dietary polyphenols.

show abstract

“…One clinical study showed that synbiotic (Lactobacillus sporogenes, inulin, and β-carotene) had favorable effects on insulin, HOMA-IR, HOMA-B, triglycerides, VLDL-cholesterol, total-/HDL-cholesterol ratio, NO, and GSH levels (Asemi et al, 2016). Many studies have proved the well therapeutic effect of synbiotics without any adverse reactions (Chiou et al, 2021;Naseri et al, 2022;Zhao et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Effects of the synbiotic composed of mangiferin and Lactobacillus reuteri 1–12 on type 2 diabetes mellitus rats

et al. 2023

View full text Add to dashboard Cite

Many synbiotics are effective for the prevention and treatment of type 2 diabetes mellitus (T2DM). In the treatment of T2DM, synbiotics often regulate the composition of intestinal flora, which autoinducer-2 (AI-2) may play an important role. Whether the changes of intestinal flora are related to AI-2 during synbiotics treatment of T2DM is a topic worth studying. We elucidated the effects of synbiotic composed of mangiferin and Lactobacillus reuteri 1–12 (SML) on T2DM rats. Male Spraque-Dawley rats were injected intraperitoneally with streptozotocin (STZ) and randomly grouped. After that, biochemical parameters, intestinal flora, fecal AI-2, and intestinal colonization of L. reuteri were detected. The results showed that SML had a hypoglycemic effect and mitigated the organ lesions of the liver and pancreas. Also, SML regulated biochemical parameters such as short chain fatty acids (SCFAs), lipopolysaccharides (LPS), intercellular cell adhesion molecule-1 (ICAM-1), and tumor necrosis factor-α (TNF-α). On the other hand, the proportion of probiotics, such as Lactobacillus acidophilus, L. reuteri, Bifidobacterium pseudolongum, Lactobacillus murinus, and Lactobacillus johnsonii, were elevated by the treatment of SML. In addition, SML promoted the colonization and proliferation of L. reuteri in the gut. Another thing to consider was that AI-2 was positively correlated with the total number of OTUs sequences and SML boosted AI-2 in the gut. Taken together, these results supported that SML may modulate intestinal flora through AI-2 to treat T2DM. This study provided a novel alternative strategy for the treatment of T2DM in future.

show abstract

Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease

Cited by 11 publications

References 80 publications

Pharmacological Mechanisms and Clinical Applications of Curcumin: Update

Pharmacological Mechanisms and Clinical Applications of Curcumin: Update

Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization

Effects of the synbiotic composed of mangiferin and Lactobacillus reuteri 1–12 on type 2 diabetes mellitus rats

Contact Info

Product

Resources

About